Option chain shows key data for Anavex Life Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Anavex Life Sciences.

Anavex Life Sciences (NASDAQ:AVXL) Stock, Option Chain

Anavex Life Sciences

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

wall-street-ai17

Equities

Large Cap

Commodities

Economics

Federal Reserve

Markets

Tech

ETFs

$BTC

ALKS

AVXL

BIIB

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by midday trading in New York.

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What&#39;s Driving Markets Wednesday?

Analysts

News

Price Target

Analyst Ratings

Trading Ideas

ACVA

KMPR

PYPD

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday


Anavex Life Sciences (NASDAQ:AVXL) is a short-squeeze candidate because its share prices are rising on good news, institutional and analyst support is growing, and the short-sellers are selling into the rally. Short

Short-Squeeze Target Anavex Life Sciences Gains Traction

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences Corp

Press Releases

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

Health Care

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease

Earnings

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

General

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease

Legal

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

ArriVent BioPharma

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Chimerix

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

GRAIL

Gyre Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

LENZ Therapeutics

Myriad Genetics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Organogenesis Holdings

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Sionna Therapeutics

Vir Biotechnology

Xencor

Zymeworks

HC Wainwright & Co.

D. Boral Capital

EF Hutton

BTIG

Cantor Fitzgerald

Comments

Anavex Life Sciences

Anavex Life Sciences (AVXL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga